Lanza, Gregory M
- Washington University in St. Louis · Internal Medicine (NIH department code)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
FY2022 NIH rank #18,897
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2022Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award categories
- Internal Medicine
NIH Funding · FY2022
Linked Award Amount
$610.5K
Full award amounts, FY2022
Award Records
1
Records listing this PI
Award-Linked Rank
#18,897
By linked amount among FY2022 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2022 award records by amount
NIH award records listing Lanza, Gregory M as a PI. Multi-PI records show the full award amount for context.
- 5R01CA216840-05R01Contact PIOVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPYWashington University in St. Louis · Internal Medicine (NIH department code)$610.5Kaward amount
Award organization
Organizations that administered FY2022 awards listing Lanza, Gregory M as a PI.
FY2022 award administered by Washington University in St. Louis (MO).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardWashington University in St. Louis
- 2007$500K Cumulative Funding
- 2007$1M Cumulative Funding
- 2007Entered Top 50% NationallyRanked #7229
- 2009$2M Cumulative Funding
- 2011R01 Grant Holder
- 2012$5M Cumulative Funding
- 2018$10M Cumulative Funding